CL2012000991A1 - Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras. - Google Patents
Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras.Info
- Publication number
- CL2012000991A1 CL2012000991A1 CL2012000991A CL2012000991A CL2012000991A1 CL 2012000991 A1 CL2012000991 A1 CL 2012000991A1 CL 2012000991 A CL2012000991 A CL 2012000991A CL 2012000991 A CL2012000991 A CL 2012000991A CL 2012000991 A1 CL2012000991 A1 CL 2012000991A1
- Authority
- CL
- Chile
- Prior art keywords
- sglt
- modulators
- diabetes
- pharmaceutical composition
- metabolic syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Abstract
Compuestos derivados de glicósidos, moduladores de SGLT; forma cristalina de l-prolina de (2s,3r, 4r, 5s, 6r)-2-[4-cloro-3-(3,4-dihidro-2h-benzo[1,4]-oxazin-6-il-,eto)-fenil]-6-hidroxi-metil-tetrahidro-piran-3,4.5-triol; composición farmacéutica; producto combinado; y su uso en síndrome metabólico, diabetes, entre otros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2173DE2009 | 2009-10-20 | ||
IN2689DE2009 | 2009-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000991A1 true CL2012000991A1 (es) | 2012-09-07 |
Family
ID=43216622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000991A CL2012000991A1 (es) | 2009-10-20 | 2012-04-19 | Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras. |
Country Status (39)
Country | Link |
---|---|
US (7) | US8163704B2 (es) |
EP (1) | EP2491029B1 (es) |
JP (2) | JP5384744B2 (es) |
KR (2) | KR101465308B1 (es) |
CN (1) | CN102656165B (es) |
AR (1) | AR078685A1 (es) |
AU (1) | AU2010309833B2 (es) |
BR (1) | BR112012009053B1 (es) |
CA (1) | CA2777812C (es) |
CL (1) | CL2012000991A1 (es) |
CO (1) | CO6531486A2 (es) |
CR (1) | CR20120176A (es) |
CU (1) | CU24079B1 (es) |
CY (1) | CY1117409T1 (es) |
DK (1) | DK2491029T3 (es) |
EA (1) | EA023781B1 (es) |
EC (1) | ECSP12011909A (es) |
ES (1) | ES2564191T3 (es) |
GT (1) | GT201200117A (es) |
HK (1) | HK1168099A1 (es) |
HN (1) | HN2012000798A (es) |
HR (1) | HRP20160436T1 (es) |
HU (1) | HUE027531T2 (es) |
IL (1) | IL219309A (es) |
JO (1) | JO3152B1 (es) |
MA (1) | MA33737B1 (es) |
MX (1) | MX2012004700A (es) |
MY (1) | MY158326A (es) |
NZ (1) | NZ598717A (es) |
PE (1) | PE20121281A1 (es) |
PL (1) | PL2491029T3 (es) |
RS (1) | RS54563B1 (es) |
SG (1) | SG179562A1 (es) |
SI (1) | SI2491029T1 (es) |
TN (1) | TN2012000109A1 (es) |
TW (2) | TWI594756B (es) |
UY (1) | UY32958A (es) |
WO (1) | WO2011048112A1 (es) |
ZA (1) | ZA201201680B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2708538B1 (en) | 2009-03-23 | 2015-08-12 | Glenmark Pharmaceuticals S.A. | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
CN102134226B (zh) * | 2010-01-26 | 2013-06-12 | 天津药物研究院 | 一类苯基c-葡萄糖苷衍生物、其制备方法和用途 |
MX339570B (es) | 2010-05-11 | 2016-05-31 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio. |
SI2697218T1 (sl) | 2011-04-13 | 2016-07-29 | Janssen Pharmaceutica Nv | Postopek za pripravo spojin, koristnih kot zaviralci sglt2 |
US8614195B2 (en) * | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
EP2697240B1 (en) | 2011-04-14 | 2015-09-16 | Novartis AG | Glycoside derivatives and uses thereof |
TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
CN103596564B (zh) * | 2011-06-01 | 2016-05-04 | 株式会社绿十字 | 作为sglt2抑制剂的二苯基甲烷衍生物 |
CN102827122B (zh) * | 2011-06-17 | 2015-01-14 | 山东轩竹医药科技有限公司 | 糖苷衍生物 |
CN102863417B (zh) * | 2011-07-09 | 2015-01-14 | 山东轩竹医药科技有限公司 | C-糖苷衍生物 |
TWI589576B (zh) * | 2011-07-15 | 2017-07-01 | 諾華公司 | 氮雜-雙環二芳基醚之鹽類及製造彼等或其前驅物之方法 |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
UA113086C2 (xx) | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
JP6461080B2 (ja) * | 2013-03-11 | 2019-01-30 | ヤンセン ファーマシューティカ エヌ.ベー. | 二重sglt1/sglt2阻害剤 |
EP3010586A1 (en) | 2013-06-21 | 2016-04-27 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
AU2014300629A1 (en) | 2013-06-24 | 2015-12-24 | Lupin Limited | Chromane and chromene derivatives and their use as CRAC modulators |
CN104250272B (zh) * | 2013-06-27 | 2018-10-09 | 上海方楠生物科技有限公司 | 一种利用微反应器制备列净类药物中间体的方法 |
WO2015032272A1 (zh) * | 2013-09-09 | 2015-03-12 | 江苏豪森药业股份有限公司 | C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用 |
AR098670A1 (es) | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN105294624B (zh) * | 2015-11-16 | 2018-01-12 | 山东罗欣药业集团股份有限公司 | 一种达格列净的制备方法 |
HRP20211670T8 (hr) | 2016-06-17 | 2022-03-18 | Daewoong Pharmaceutical Co., Ltd. | Derivat difenilmetana u kristalnom obliku |
US10815210B2 (en) | 2016-11-10 | 2020-10-27 | Janssen Pharmaceutica Nv | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators |
CN108203432B (zh) * | 2016-12-20 | 2021-03-02 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
WO2018158744A1 (en) * | 2017-03-03 | 2018-09-07 | Novartis Ag | Sglt1/2 inhibitor lik066 for treating obesity |
JP2019517459A (ja) * | 2017-04-12 | 2019-06-24 | ノバルティス アーゲー | 心不全患者におけるlik066の使用 |
AU2018287810B2 (en) * | 2017-06-21 | 2021-03-25 | Novartis Ag | Licofligozin for the treatment of non-alcoholic steatohepatitis |
US10696662B2 (en) | 2017-08-21 | 2020-06-30 | Janssen Pharmaceutica Nv | 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators |
GB201721960D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721967D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721957D0 (en) * | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721964D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721961D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
CN112424207B (zh) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | Nlrp3炎性小体抑制剂 |
CN108863736A (zh) * | 2018-07-27 | 2018-11-23 | 福州大学 | 一种羰基功能化的芳香羧酸的制备方法 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
WO2020151620A1 (zh) * | 2019-01-24 | 2020-07-30 | 北京盈科瑞创新药物研究有限公司 | 化合物、其制备方法及其作为药物中间体的应用 |
WO2020151623A1 (zh) * | 2019-01-24 | 2020-07-30 | 北京盈科瑞创新药物研究有限公司 | 化合物、其制备方法及其作为药物中间体的应用 |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
WO2021014350A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Combination treatment of liver diseases using fxr agonists |
CN111099975A (zh) * | 2019-12-23 | 2020-05-05 | 河北合佳医药科技集团股份有限公司 | 一种5-溴-2-氯-4’-乙氧基二苯甲酮的制备方法 |
EP4249479A1 (en) * | 2020-11-19 | 2023-09-27 | Beijing Increase Innovative Drug Co., Ltd. | Glucoside derivative, and preparation method therefor and application thereof |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
US5410031A (en) * | 1992-02-24 | 1995-04-25 | The Regents Of The University Of California Office Of Technology Transfer | Nucleoside cotransporter protein cDNA |
US5410054A (en) | 1993-07-20 | 1995-04-25 | Merck Frosst Canada, Inc. | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis |
AU6024998A (en) | 1997-01-15 | 1998-08-07 | Glycomed Incorporated | Aryl c-glycoside compounds and sulfated esters thereof |
PL203124B1 (pl) | 1999-08-31 | 2009-08-31 | Kissei Pharmaceutical | Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna je zawierająca i związki pośrednie |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
JP4272319B2 (ja) * | 1999-11-30 | 2009-06-03 | アイシン精機株式会社 | ヘッドレスト装置 |
US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
JP4456768B2 (ja) | 2000-02-02 | 2010-04-28 | 壽製薬株式会社 | C−配糖体を含有する薬剤 |
BR0109323A (pt) | 2000-03-17 | 2002-12-24 | Kissei Pharmaceutical | Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
SI1329456T1 (sl) | 2000-09-29 | 2006-12-31 | Kissei Pharmaceutical | Glukopiranoziloksibenzilbenzenski derivati in zdravilni sestavki, ki vsebujejo te spojine |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
EP1392326B1 (en) | 2001-04-04 | 2009-09-09 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
CN1744916A (zh) | 2002-12-04 | 2006-03-08 | 橘生药品工业株式会社 | 预防和治疗高血糖所导致的疾病 |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
EP1444890B1 (en) | 2003-02-05 | 2009-01-07 | Hermann Koepsell | RS1 deficient transgenic animal and uses thereof |
US7202350B2 (en) * | 2003-03-14 | 2007-04-10 | Astellas Pharma Inc. | C-glycoside derivatives and salts thereof |
AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
CA2549017A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-o-glucosides |
AR045173A1 (es) * | 2003-08-01 | 2005-10-19 | Tanabe Seiyaku Co | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio |
CA2539032A1 (en) | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof |
BRPI0508259A (pt) | 2004-03-04 | 2007-07-31 | Kissei Pharmaceutical | derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo |
US7732596B2 (en) | 2004-03-04 | 2010-06-08 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
WO2006010557A1 (de) * | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
AU2005286494B2 (en) | 2004-09-22 | 2011-06-23 | Vib Vzw | Intestinal epithelial glucose sensor |
DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
WO2006054629A1 (ja) | 2004-11-18 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | 1-置換-3-(β-D-グリコピラノシル)含窒素ヘテロ環化合物、及びそれを含有する医薬 |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
JP5230613B2 (ja) * | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
WO2008115574A1 (en) | 2007-03-21 | 2008-09-25 | Reliant Pharmaceuticals, Inc. | Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same |
TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
DK2147315T3 (da) | 2007-04-18 | 2013-09-23 | Tethys Bioscience Inc | Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf |
WO2009026389A2 (en) | 2007-08-20 | 2009-02-26 | Mount Sinai School Of Medicine | Regulating glp-1 and sglt-1 in gastrointestinal cells |
PL2187742T3 (pl) | 2007-08-23 | 2018-06-29 | Theracos Sub, Llc | Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
MX2010007426A (es) * | 2008-01-31 | 2010-08-18 | Astellas Pharma Inc | Composiciones farmaceuticas para tratar trastorno del higado graso. |
US8518895B2 (en) | 2008-05-22 | 2013-08-27 | Bristol-Myers Squibb Company | Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same |
CA2725047A1 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
US8603989B2 (en) | 2008-05-22 | 2013-12-10 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same |
JP2012502950A (ja) | 2008-09-19 | 2012-02-02 | ノバルティス アーゲー | グリコシド誘導体およびその使用 |
MX2011002990A (es) | 2008-09-19 | 2011-04-11 | Novartis Ag | Derivados de glucosido y usos de los mismos como inhibidores de sglt. |
WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20100167988A1 (en) | 2008-10-22 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
WO2010074219A1 (ja) | 2008-12-26 | 2010-07-01 | アステラス製薬株式会社 | ベンゾチオフェン化合物 |
WO2010080976A1 (en) | 2009-01-09 | 2010-07-15 | Sdg, Inc. (An Ohio Corporation) | Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments |
CN102316875A (zh) | 2009-02-13 | 2012-01-11 | 贝林格尔.英格海姆国际有限公司 | 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂 |
AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010128152A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2010
- 2010-10-18 US US12/906,682 patent/US8163704B2/en active Active
- 2010-10-19 EA EA201200600A patent/EA023781B1/ru not_active IP Right Cessation
- 2010-10-19 NZ NZ598717A patent/NZ598717A/en not_active IP Right Cessation
- 2010-10-19 SI SI201031162A patent/SI2491029T1/sl unknown
- 2010-10-19 SG SG2012016820A patent/SG179562A1/en unknown
- 2010-10-19 DK DK10768927.5T patent/DK2491029T3/en active
- 2010-10-19 CN CN201080044483.5A patent/CN102656165B/zh active Active
- 2010-10-19 MX MX2012004700A patent/MX2012004700A/es active IP Right Grant
- 2010-10-19 TW TW105117771A patent/TWI594756B/zh not_active IP Right Cessation
- 2010-10-19 RS RS20160112A patent/RS54563B1/en unknown
- 2010-10-19 TW TW099135639A patent/TWI558723B/zh not_active IP Right Cessation
- 2010-10-19 CA CA2777812A patent/CA2777812C/en active Active
- 2010-10-19 PL PL10768927T patent/PL2491029T3/pl unknown
- 2010-10-19 KR KR1020127012873A patent/KR101465308B1/ko active IP Right Grant
- 2010-10-19 CU CU2012000062A patent/CU24079B1/es active IP Right Grant
- 2010-10-19 EP EP10768927.5A patent/EP2491029B1/en active Active
- 2010-10-19 PE PE2012000511A patent/PE20121281A1/es active IP Right Grant
- 2010-10-19 KR KR1020147008569A patent/KR20140054415A/ko not_active Application Discontinuation
- 2010-10-19 MY MYPI2012001056A patent/MY158326A/en unknown
- 2010-10-19 ES ES10768927.5T patent/ES2564191T3/es active Active
- 2010-10-19 WO PCT/EP2010/065747 patent/WO2011048112A1/en active Application Filing
- 2010-10-19 BR BR112012009053-4A patent/BR112012009053B1/pt not_active IP Right Cessation
- 2010-10-19 JP JP2012534672A patent/JP5384744B2/ja active Active
- 2010-10-19 AU AU2010309833A patent/AU2010309833B2/en active Active
- 2010-10-19 HU HUE10768927A patent/HUE027531T2/en unknown
- 2010-10-20 JO JOP/2010/0359A patent/JO3152B1/ar active
- 2010-10-20 UY UY0001032958A patent/UY32958A/es active IP Right Grant
- 2010-10-20 AR ARP100103826A patent/AR078685A1/es active IP Right Grant
-
2012
- 2012-03-07 ZA ZA2012/01680A patent/ZA201201680B/en unknown
- 2012-03-09 TN TNP2012000109A patent/TN2012000109A1/en unknown
- 2012-03-21 US US13/425,888 patent/US8466114B2/en active Active
- 2012-04-12 CR CR20120176A patent/CR20120176A/es unknown
- 2012-04-19 IL IL219309A patent/IL219309A/en active IP Right Grant
- 2012-04-19 HN HN2012000798A patent/HN2012000798A/es unknown
- 2012-04-19 CL CL2012000991A patent/CL2012000991A1/es unknown
- 2012-04-20 GT GT201200117A patent/GT201200117A/es unknown
- 2012-04-26 CO CO12068967A patent/CO6531486A2/es active IP Right Grant
- 2012-05-11 MA MA34854A patent/MA33737B1/fr unknown
- 2012-05-17 EC ECSP12011909 patent/ECSP12011909A/es unknown
- 2012-09-11 HK HK12108866.0A patent/HK1168099A1/zh not_active IP Right Cessation
- 2012-09-13 US US13/614,534 patent/US8828951B2/en active Active
-
2013
- 2013-10-02 JP JP2013207478A patent/JP2014040451A/ja active Pending
-
2014
- 2014-05-30 US US14/291,268 patent/US20140274921A1/en not_active Abandoned
-
2015
- 2015-01-23 US US14/604,173 patent/US20150141354A1/en not_active Abandoned
-
2016
- 2016-04-19 CY CY20161100330T patent/CY1117409T1/el unknown
- 2016-04-20 US US15/134,016 patent/US9895389B2/en not_active Ceased
- 2016-04-21 HR HRP20160436TT patent/HRP20160436T1/hr unknown
-
2020
- 2020-02-18 US US16/793,734 patent/USRE49080E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012000991A1 (es) | Compuestos derivados de glicosidos, moduladores de sglt; composicion farmaceutica; y su uso en el sindrome metabolico para tratar enfermedades como diabetes, resistencia a la insulina, disminucion en la tolerancia a la glucosa, entre otras. | |
CL2009001595A1 (es) | Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad. | |
CL2013002973A1 (es) | Compuestos derivados de esteres de fenilglucopiranosil sustituidos mediadores del co-transportador sodio/d-glucosa (sglt); composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento del sindrome metabolico, sindrome x, diabetes, resistencia a la insulina, entre otros | |
DOP2011000058A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol utiles para usar como inhibidores del transportador de sodio-glucosa | |
NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
PL2187742T3 (pl) | Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy | |
WO2012165914A3 (en) | Novel diphenylmethane derivatives as sglt2 inhibitors | |
BR112013028744A2 (pt) | cocristais de ácido cítrico e de l-prolina de (2s,3r,4r,5s,6r)-2(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6-(hidroximetil)tetra-hidro-2h-piran-3,4,5-triol | |
MX2012002942A (es) | Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno. | |
CL2009001203A1 (es) | Compuestos derivados de indazol y pirazol sustituidos; composicion farmaceutica de dichos compuestos; kit farmaceutico; y su uso como activadores de la glucoquinasa para tratar enfermedades metabolicas tales como hiperglicemia, diabetes, dislipidemias, obesidad, sindrome metabolico x y enfermedades cardiovasculares. | |
MX2013014843A (es) | Oxazepinas como moduladores del canal de iones. | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
TN2011000416A1 (en) | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient | |
CL2012001336A1 (es) | Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas. | |
TR201901262T4 (tr) | (2S,3R,4R,5S,6R)-2-(4-Kloro-3-(4-Etoksibenzil)Fenil)-6-(Metiltiyo)Tetrahidro-2H-Piran-3,4,5-Triol İçeren Bileşimler | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
CL2011002041A1 (es) | Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes. | |
WO2012006014A3 (en) | Multi-component pharmaceuticals for treating diabetes | |
BR122019018186B8 (pt) | cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica | |
BRPI0910491A2 (pt) | Métodos para produzir uma solução de glicose aquosa e uma substância orgânica por fermentação, solução de glicose, glúten, usos de uma solução de glicose e de um glúten, e, composição alimentícia. | |
CR11398A (es) | Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo. | |
AR084832A1 (es) | Derivado cristalino de oxazina | |
CL2009001366A1 (es) | Compuestos derivados de heterociclil-sulfonamidas con un grupo de cabeza de heterociclo y oxadiazolona; composicion farmaceutica y su proceso de preparacion; y su uso para el tratamiento y/o prevencion de trastornos del metabolismo de acidos grasos y de la glucosa, tal como diabetes mellitus, resistencia a la insulina, dislipidemias, entre otras. | |
NZ630385A (en) | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance | |
CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. |